Phase I Study of Cytokine Induced Memory-Like Natural Killer Cells Combined With Atezolizumb in Subjects With Relapsed or Refractory Acute Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
Summary
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Eligibility
- Age range
- 18–70 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Disease specific inclusion criteria: * Subjects must have histologically confirmed acute myeloid leukemia that meets any of the following criteria: * Refractory to at least two attempts at prior induction therapy. An attempt is defined as either a single cycle of combination chemotherapy such as daunorubicin/anthracycline OR a single monthly cycle of a hypomethylating agent with venetoclax. * Patients with FLT3-ITD or -TKD mutations must have received at least one commercially available inhibitor of FLT3. * Patients with NPM1 mutation or rearrangements of MLL must…